A mouse model for HBV immunotolerance and immunotherapy-Reference-Cited by-同舟云学术

A mouse model for HBV immunotolerance and immunotherapy

Published:2013-09-30 Issue:1 Volume:11 Page:71-78
ISSN:1672-7681
Container-title:Cellular & Molecular Immunology
language:en
Short-container-title:Cell Mol Immunol

Author:

Yang Dan,Liu Longchao,Zhu Danming,Peng Hua,Su Lishan,Fu Yang-Xin,Zhang Liguo

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/cmi201343.pdf

Reference35 articles.

1. World Health Organization. Hepatitis B. Fact sheet. Geneva: SWHO, 2012. Available from: http://www.who.int/mediacentre/factsheets/fs204/en . Accessed on May 10th, 2013.

2. Scaglione SJ, Lok AS . Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012; 142: 1360–1368.e1.

3. Chen DS . Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010; 25: 19–25.

4. Pol S, Michel ML . Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006; 5: 707–716.

5. Schirmbeck R, Wild J, Stober D, Blum HE, Chisari FV, Geissler M et al. Ongoing murine T1 or T2 immune responses to the hepatitis B surface antigen are excluded from the liver that expresses transgene-encoded hepatitis B surface antigen. J Immunol 2000; 164: 4235–4243.

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical characterization of a novel potent core protein assembly modulator for the treatment of chronic hepatitis B viral infection;European Journal of Pharmaceutical Sciences;2024-09

2. TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse models;Emerging Microbes & Infections;2024-08-08

3. Integrated network pharmacology and metabolomics to study the potential mechanism of Jiawei Yinchenhao decoction in chronic hepatitis B;Heliyon;2024-08

4. Selective depletion of HBV-infected hepatocytes by class A capsid assembly modulators requires high levels of intrahepatic HBV core protein;Antimicrobial Agents and Chemotherapy;2024-07-09

5. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection;Signal Transduction and Targeted Therapy;2024-06-21